Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

25.07 +0.19 (+0.76%)
Streaming Delayed Price Updated: 10:36 AM EST, Dec 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Moderna (MRNA) Deep-Dive: Navigating the 7.5% Year-End Slide and the Path to a 2028 Recovery
As of December 24, 2025, Moderna, Inc. (Nasdaq: MRNA) finds itself at a pivotal crossroads in its corporate evolution. Once the definitive success story of the pandemic era, the Cambridge-based... 
Via PredictStreet
Topics Initial Public Offering
News headline image
Sanofi’s $2.2 Billion Strategic Pivot: Deconstructing the Dynavax Acquisition and the Future of Specialty Medicine
As of today, December 24, 2025, the global pharmaceutical landscape is witnessing a profound consolidation of power within specialty medicine and immunology. Sanofi (NASDAQ: SNY; Euronext: SAN), the... 
Via PredictStreet
Topics Artificial Intelligence Economy Intellectual Property
Pfizer Confirms Death Of Patient Enrolled In Hemophilia Drug Study ↗
Via Stocktwits
News headline image
“Setting Up The Second Act” Stock Market (And Sentiment Results)… ↗
Pfizer stands as one of the world’s largest pharmaceutical companies, with a broad portfolio spanning vaccines, oncology, and immunology. 
Via Talk Markets
News headline image
Is Fidelity Medical Equipment the Ultimate "Forever Fund" for Health Care Investors? ↗
This basket of 64 medical device stocks could raise its dividend for decades. 
Via The Motley Fool
Topics ETFs Government Supply Chain
News headline image
Novo Nordisk Stock Soars as "Wegovy Pill" Gains FDA Approval, Reshaping Obesity Market
Shares of Novo Nordisk (NYSE: NVO) surged more than 8% in early trading on December 23, 2025, after the pharmaceutical giant secured a landmark FDA approval for its high-dose oral semaglutide, branded... 
Via MarketMinute
News headline image
The Next Big Buyout? Abivax Emerges as a Premier M&A Contender for 2026 Amidst Biotech Consolidation Wave
As the biotech sector closes out a transformative 2025, one name has risen to the top of every institutional investor's watchlist: Abivax (NASDAQ: ABVX). Following a year of stellar clinical results... 
Via MarketMinute
Topics Intellectual Property
News headline image
Novo Nordisk Breaks the Mold: Oral Obesity Breakthrough Sends Shares to New Heights as Pharma Landscape Shifts
BAGSVAERD, Denmark — In a landmark decision that has sent shockwaves through the global pharmaceutical industry, Novo Nordisk (NYSE:NVO) has secured U.S. Food and Drug Administration (FDA) approval for... 
Via MarketMinute
Topics Economy
News headline image
Explore the S&P500 index on Tuesday and find out which stocks are the most active in today's session. ↗
Stay informed about the most active stocks in the S&P500 index on Tuesday's session. Discover the stocks that are generating the highest trading volume and driving market activity. 
Via Chartmill
News headline image
Pfizer Reports Patient Death In Marstacimab Hemophilia Extension Study ↗
Pfizer disclosed a patient death in a marstacimab hemophilia study, triggering a safety review and reassessment of surgical protocols. 
Via Benzinga
News headline image
The Great Biotech Rebound: How Pricing Clarity Rescued the Drug Sector in 2025
After a tumultuous first half of 2025 that saw the pharmaceutical and biotechnology sectors languish under a cloud of regulatory dread, the industry is ending the year on a surprisingly high note. The... 
Via MarketMinute
Topics Economy
News headline image
The Great Consolidation: Why 2026 is Set to Become the 'Year of the Mega-Deal'
As the curtain closes on 2025, the global financial landscape is witnessing a seismic shift in corporate strategy. After two years of "wait-and-see" posturing dictated by high interest rates and... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
News headline image
The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally
As the curtains draw on 2025, the biotechnology sector has emerged as the undisputed champion of the equity markets, staging a dramatic year-end rally that has caught even the most optimistic analysts... 
Via MarketMinute
Topics ETFs Economy Intellectual Property
News headline image
The Incretin Empire: Eli Lilly’s (LLY) Path to a $1 Trillion Market Cap and Beyond
As of December 22, 2025, the global equity markets are witnessing a historic recalibration of the healthcare sector. For decades, the "Trillion Dollar Club" was an exclusive enclave for Silicon... 
Via PredictStreet
Topics Economy Intellectual Property
News headline image
The Pfizer Pivot: A Deep-Dive into PFE’s 2025 Financial Recovery and Strategic Rebirth
As of today, December 22, 2025, Pfizer Inc. (NYSE: PFE) stands as a case study in corporate reinvention and the brutal reality of the post-pandemic "hangover." Once the darling of the global healthcare... 
Via PredictStreet
Topics Economy Intellectual Property
News headline image
Moderna (MRNA): The “Act 2” of an mRNA Pioneer – A 2025 Deep Dive
As of December 22, 2025, Moderna, Inc. (NASDAQ: MRNA) stands at a critical juncture in its corporate evolution. Once the poster child for the biotechnology industry’s rapid response to the global... 
Via PredictStreet
Topics Earnings Initial Public Offering Intellectual Property
News headline image
Should You Forget Novo Nordisk and Buy This Magnificent High-Yield Drug Stock Instead? ↗
Novo Nordisk gained a head start in the GLP-1 race but then fell behind; Pfizer is working hard to catch up to the new leader. 
Via The Motley Fool
MarketBeat Week in Review – 12/15 - 12/19 ↗
Via MarketBeat
News headline image
Better Buy in 2026: Pfizer or Merck? ↗
This year has been one to forget for these pharmaceutical giants. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Trump Strikes New Drug-Price Deals With Roche, Novartis, Merck And Other Pharma Giants ↗
The deals expand the pricing program to most targeted drugmakers in exchange for temporary tariff relief. 
Via Stocktwits
Topics Government World Trade
News headline image
Dow Jones' Merck, Other Drugmakers Strike Drug-Pricing Bargains With Trump ↗
Dow Jones stock Merck forged a Most Favored Nation agreement with the Trump administration on Friday. 
Via Investor's Business Daily
Topics Government Stocks
News headline image
Friday's session: most active stock in the S&P500 index ↗
Curious about the most active S&P500 stocks in today's session? Join us as we explore the US markets on Friday and uncover the stocks that are leading the way in terms of trading volume and market... 
Via Chartmill
News headline image
Down 80%, Should You Buy the Dip on Moderna? ↗
Your decision on whether to invest now depends to some extent on your investment strategy. 
Via The Motley Fool
News headline image
1 S&P 500 Stock with Impressive Fundamentals and 2 That Underwhelm
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural... 
Via StockStory
Topics Stocks
News headline image
3 Absurdly Cheap Stocks You Can Buy For Less than $100 Right Now ↗
The stocks listed here trade at forward earnings multiples of less than 18. 
Via The Motley Fool
News headline image
Better Buy in 2026: Pfizer or Eli Lilly? ↗
These two stocks have been going in opposite directions over the past few years. 
Via The Motley Fool
Topics World Trade
News headline image
Flying Blind: How the Record 43-Day Shutdown Blinded the Fed and Rattled Global Markets
The United States economy is finally emerging from a period of unprecedented statistical darkness. Following the conclusion of the longest government shutdown in American history—a 43-day impasse that... 
Via MarketMinute
Topics Artificial Intelligence Bonds Credit Cards
News headline image
The Weight of a Trillion: Inside Eli Lilly’s Pharmaceutical Hegemony
On this day in late 2025, Eli Lilly and Company (NYSE: LLY) stands as the undisputed titan of the global pharmaceutical industry. Having crossed the historic $1 trillion market capitalization threshold... 
Via PredictStreet
Topics Economy World Trade
News headline image
Industry Comparison: Evaluating Pfizer Against Competitors In Pharmaceuticals Industry ↗
 
Via Benzinga
News headline image
Pfizer Invites Public to View and Listen to Webcast of February 3 Conference Call with Analysts
From Pfizer Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.